Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Advances in Redox Research is Scopus-indexed (Q1, CiteScore 6.6), WoS ESCI, DOAJ. Published by Elsevier Inc..
Checked against the index lists dated .
ISSN 2667-1379Verify ISSN ↗
Publisher: Elsevier Inc.
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biochemistry, Genetics and Molecular Biology (miscellaneous) | 23 / 144 | 84th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2021–present, best quartile Q1, CiteScore 6.6.
Advances in Redox Research is Q1 in Biochemistry, Genetics and Molecular Biology (miscellaneous) (rank 23 of 144), by CiteScore 2025.
Advances in Redox Research is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 6.6, which places it in quartile Q1 at the 84th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.959, quartile Q2, with an H-index of 15.
The publisher lists an article processing charge of about US$1,590 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Advances in Redox Research is published by Elsevier Inc. Its ISSN is 2667-1379.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Advances in Redox Research has an h-index of 19 and a 2-year mean of 3.68 citations per paper (OpenAlex). Its Scopus CiteScore is 6.6, quartile Q1. On 2-year citations it ranks #42 of 141 Scopus journals in Biochemistry, Genetics and Molecular Biology (miscellaneous).
Advances in Redox Research published 28 papers in 2025; its busiest recent year was 2023 with 30. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 90 research articles (2024–2026), authors are most often from United States (16.5%), China (16.3%) and India (12.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 1 retracted paper is recorded (5.5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.